cor2ed
engage checkpoint medical linkedin twitter
bg

Join the expert discussion: Treatment options for HCC patients not eligible for immunotherapy

Join the expert discussion: Treatment options for HCC patients not eligible for immunotherapy

You are invited to join our interactive online event hosted by international experts

You are invited to join our interactive online event hosted by international experts

Come and join your peers in this 90-minute interactive Experts Knowledge Share: Treatment options for HCC patients who are not eligible for or progressed on IO. Clinical considerations, and when to switch.

You will receive a €100 honorarium for your active participation.

 

Tuesday, 23rd May 2023

12:00-13:30 BST / 13:00-14:30 CEST / 07:00-08:30 EST / 20:00-21:30 JST

Register below

 

A panel of independent experts will explore the outcomes of patients with HCC receiving 1st line IO and address the question: when is the right time to switch? They'll also discuss the treatment options for patients with HCC who are not eligible for IO in 1st line and review the data supporting 2nd line treatment options and how to achieve optimal sequencing.

We welcome your participation and invite you to submit questions for the panel in advance or ask questions during the event.

 

 

Prof. Michel Ducreux

Head of GI Oncology

Gustave Roussy Cancer Centre

France

Dr Timon Vandamme

Medical Oncologist

University Hospital Antwerp

Belgium

Portrait of Changhoon Yoo
Asst. Prof. Changhoon Yoo

Medical Oncologist

Asan Medical Center

South Korea

preview next

Meeting Chair: Prof. Michel Ducreux

Co-chairs: Dr Timon Vandamme and Assoc. Prof. Changhoon Yoo

This event is brought to you in collaboration with HCC CONNECT, a group of independent international experts specialising in liver oncology.

 

This programme is endorsed by:

 

 

Digestive Cancers Europe (DiCE) is the European umbrella organisation of a large group of national members representing patients with digestive cancer – colorectal, gastric, liver, oesophageal, pancreatic and rare cancers. Our mission is to contribute to early diagnosis and decreased mortality from digestive cancers and to increase overall survival and quality of life.

DiCE is running a survey to map the availability of liver cancer treatments across the EU. The aim is to aid broader access to best-practice care to ultimately increase liver cancer survival rates across Europe. Can you spare 15 minutes to share what treatments are available in your EU country? Take the survey.

This educational programme is supported by an Independent Medical Education Grant from Bayer

HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer, AstraZeneca and from Eisai Europe Limited.

Other programmes of interest

preview next